CONTACT 040 6761 1600 / 6761 1700 neuland@neulandlabs.com neulandlabs.com



November 6, 2024

To **BSE Limited** Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Investors/Analysts Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the presentation to the Investors/ Analysts on the Financial Results of the Company for the quarter and half year ended September 30, 2024.

The presentation is also being uploaded on the website of the Company at <u>www.neulandlabs.com</u>.

This is for your information and records.

Yours sincerely, For **Neuland Laboratories Limited**

Sarada Bhamidipati Company Secretary

Encl: As above



Neuland Laboratories Limited

Investor Presentation Q2FY25 & H1FY25

SAFE HARBOUR

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Table of Content





3

Q2FY25 & H1FY25 Highlights

Management Commentary





SUCHETH DAVULURI

"The numbers of this quarter are subpar relative to how the business has been performing over the last few quarters. However, they are in line with our commentary right at the beginning of the year as to how we see FY25 panning out. The inherent uneven nature of our business means that annual progression is a better indicator of the company's prospects than quarterly performance. We continue to make progress on our strategic plans and are enthusiastic about sustainable long-term growth driven by customer acquisitions, deepening capabilities, agile capacity expansion and optimization of processes."

SAHARSH DAVULURI

"The revenues this quarter were driven by a few key molecules on the commercial CMS and GDS specialty side. Completion of additional manufacturing facilities in this year coupled with anticipated commercial launch of molecules on the CMS side gives us the confidence of achieving high growth in FY26 and beyond. We believe that the environment remains favourable for us in the medium to long term as indicated by customer interest and addition of early-stage projects."



Business and Financial Highlights





H1FY25 Business and Financial Highlights

CMS

CMS revenues driven by commercial molecules. Increasing interest from Biotech leading to increase in early-stage projects

GDS

Specialty business driven by Paliperidone In Prime segment Mirtazapine, Levetiracetam, Escitalopram and Ezetimibe were the key molecules

Free Cash Flow (FCF) generation and utilisation


Generated Free Cash Flow of Rs. 45.8 crores during H1FY25, partly utilised in term loan repayment of Rs 17.1 crores Capex Investment of Rs. 103.5 crores





Working Capital


Working capital days of sale at 112 days as against 107 days in Q1 FY25, Mainly on account of increase in inventory days

Q2FY25 Financial Highlights












- Total Income for Q2FY25 at Rs. 315.2 crore (-25.1% YoY)
- EBITDA for Q2FY25 at Rs. 65.7 crore (-53.2% YoY)
- EBITDA Margin for Q2FY25 at 20.8% (decreased by 1260 bps YoY)
- PAT for Q2FY25 at Rs. 32.0 crore (-64.1% YoY)*
- Net Debt stood at Rs. (94.3) crore as at Q2FY25 end compared to Rs. (39.2) crore as at Q2FY24 end and Rs (110.2) crore as at Q1FY25 end


H1FY25 Financial Highlights







- Total Income for H1FY25 at Rs. 759.6 crore (-3.3% YoY)
- EBITDA for H1FY25 at Rs. 194.3 crore (-18.9% YoY)
- EBITDA Margin for H1FY25 at 25.6% (decreased by 490 bps YoY)
- PAT for H1FY25 at Rs. 130.3 crore (-13.9% YoY)*
- Net Debt stood at Rs. (94.3) crore as at H1FY25 end compared to Rs. (39.2) crore as at H1FY24 end

Key Balance Sheet Metrics








Particulars (Rs Cr)	Mar-21	Mar-22	Mar-23	Mar-24	Sep-24
Shareholder's Funds	781.9	835.6	988.4	1,276.5	1,388.5
Net Debt*	152.1	212.0	62.9	-32.6	-94.3
Tangible Assets (including CWIP and Investment property)	437.9	497.2	511.2	575.4	670.0**
Working Capital	308.6	376.9	463.0	525.4	464.1

*Net debt includes investment in Mutual Fund


**Investment property is re-classified as Assets classified as held for sale - Rs 14.0 cr in Sep-24

Key Operating Metrics Q2FY25



- Steady shift from low margin Prime to high margin Specialty and CMS segments
- CMS business caters to Innovator customers on an exclusive basis, developing and manufacturing APIs/Intermediates in line with rigorous customer expectations hence is highly concentrated in terms of customers
- Specialty segment works on complex products and technologies, hence has a focused approach towards select customers


Key Operating Metrics H1FY25




- Steady shift from low margin Prime to high margin Specialty and CMS segments
- CMS business caters to Innovator customers on an exclusive basis, developing and manufacturing APIs/Intermediates in line with rigorous customer expectations hence is highly concentrated in terms of customers
- Specialty segment works on complex products and technologies, hence has a focused approach towards select customers

CMS – Revenue Split & Number of Active Projects







Q2FY25	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg [*]	Commercial	Total
API	10	10	11	3	7	9	50
Intermediate	10	7	10	4	6	10	47
Grand Total	20	17	21	7	13	19	97
0251/24		D 4	D 3	D 2			
Q2FY24	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg	Commercial	Total
API	12	6	12	3	9	8	50
Intermediate	6	4	8	4	6	11	39
Grand Total	18	10	20	7	15	19	89
Q2FY23	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg	Commercial	Total
API	16	4	7	6	7	9	49
Intermediate	10	6	2	1	7	12	38
Grand Total	26	10	9	7	14	21	87
Q2FY22	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg	Commercial	Total
API	15	3	8	4	10	7	47
Intermediate	7	5	2	0	8	11	33

No. of active CMS projects


• Pre-clinical to P-3: Neuland generates revenue by process research & development as well manufacturing quantities for clinical trials

- *Pre-Reg/Reg: Phase-3 complete; Molecules filed but not yet commercial (Earlier labelled as 'Development') or where customer working towards adding Neuland as a second source for a commercial molecule
- Commercial: Neuland generates revenues by manufacturing APIs for commercial novel molecules for innovators
- Steady trend in molecules transitioning from clinical phases to commercialisation resulting in increase in revenue from commercial products

Company Overview


Company Overview






Key Facts





Board Of Directors





 Dr. Davuluri
 Rama Mohan Rao Executive Chairman



D. Sucheth Rao Vice Chairman & Chief Executive Officer



 D. Saharsh Rao
 Vice Chairman & Managing Director



Dr. Christopher M. Cimarusti Non-executive Director



Ms. Pallavi Joshi Bhakru Independent Director



Ms. Nirmala Murthy Independent Director



Mr. Homi Rustam Khusrokhan Independent Director




Mr. Prasad Raghavan Menon Independent Director




Mr. Sugata Sircar Independent Director

Key Milestones

Our Journey




N



Manufacturing Facilities Overview





Adding capacities for backward integration and new business

State-of-the-art R&D Centre

N

Infrastructure

- 15 Development Labs with space for expansion
- 70 Fume hoods
- Analytical Labs
- Dedicated Kilo Lab for Scale up
- Dedicated Labs for Peptides
- Approvals for DSIR, Govt. of India and USFDA
- R&D Team of 360 People
- 600 MHz NMR



Neuland's R&D facility had been inspected by USDFA in February 2016 with zero observations

Significant R&D achievements


- Several NCE APIs added in NDA or commercial stage drugs
- Support for multiple APIs each year in Phase 2 and Phase 3 clinical candidates

Generic API business

- 978+ DMFs filed
- 300+ API processes developed
- 204+ patents filed
- 3 new DMFs filed in FY24
- 1 New DMF filed in Q1 FY25

Regulatory Filings





** The numbers on this slide reflect the number of filings, the number of active filings could vary as geographic filings are merged and changes in product portfolio

Financial Highlights FY2015-2024

Rs. Cr

	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Total Income	469.9	511.6	588.9	533.7	670.3	766.6	953.0	953.2	1,200.9	1,571.1
EBITDA	67.4	81.5	106.9	54.6	61.4	105.3	162.5	144.3	281.1	474.5
EBITDA Margin	14.3%	15.9%	18.1%	10.2%	9.2%	13.7%	17.1%	15.1%	23.4%	30.2%
PAT	15.8	26.4	46.4	11.8	16.1	15.9	80.3	63.5	163.1	299.6
PAT Margin	3.4%	5.2%	7.9%	2.2%	2.4%	2.1%	8.4%	6.7%	13.6%	19.1%
EPS	18.5	29.7	41.6	10.6	12.8	12.4	62.6	49.5	127.1	233.5
Current Ratio (x)	1.1	1.2	1.3	1.2	1.4	1.4	1.5	1.6	1.7	2.1
ROCE (%)	15.7%	18.4%	15.9%	5.0%	4.7%	8.9%	13.5%	9.7%	21.3%	32.8%
Fixed Asset Turnover (x)	3.8	3.7	3.8	3.2	2.9	2.3	2.4	2.1	2.7	3.1
Debt to Equity (x)	1.1	0.9	0.7	0.5	0.3	0.3	0.2	0.3	0.1	0.1

- Revenue was impacted in FY2018 as a result of mismatch in capacity vs orders. EBITDA margins in FY19 & FY20 were impacted as a result of spike in RM prices, which led Neuland to actively work towards Supply chain de-risking before the COVID19 pandemic
- ROCE was impacted by due to acquisition of unit III in FY2018 which was commercialized in FY2021. Unit 3 utilisation levels have recently started ramping up and momentum is expected to continue

Business Strategy

Neuland Strategy Framework





Our Businesses

Generic APIs (GDS)





- We are a preferred service provider in the manufacturing of Active Pharmaceutical Ingredients (APIs)
- Process Investigation Department (PID) majorly helps our customers to meet their price pressures by way of cutting their total cost of ownership in developing an API thereby achieving excellence in Process development

- API manufacturing heritage of over 40 years
- Flexible 100g to hundreds of tons capacity
- Non-competitive advantage (does not compete in finished formulation)
- Worldwide customer base in 80+ countries
- Proven project management systems
- Impeccable EHS record








Three US FDA and cGMP compliant manufacturing facilities

100 APIs across 10 diverse areas



Total capacity of the reactor volume 941,000 liters

CDMO Services (CMS)



00000

Chemistry & manufacturing capabilities Synthetic portion of Carbohydrate fermented molecules chemistry Deuterated

Cyclic and **PEGylated** peptides

Organometallic carboncarbon bond formation

Heterocyclic

compounds

Cyanation, hydrogenation, bromination, cryogenic

Steroidal bile acids & vitamin D derivatives

Chiral compounds manufacturing

Facilities & Capacity




Three US FDA and cGMP compliant manufacturing facilities



Shareholder Information

Shareholding Details



Share Information (as on 30th September 2024)

NSE Ticker	NEULANDLAB
BSE Ticker	524558
Market Cap (Rs. Cr)	15,898
% free-float	67.36%
Free-float market cap (Rs. Cr)	10,709
Shares Outstanding	1,28,29,889
3M Average Daily Traded Volume (ADTV) (Shares)*	49,508
3M Average Daily Traded Value (In Rs. Cr)*	53.11
Industry	Pharmaceuticals

* Source: BSE & NSE


Annexure

Profit & Loss Snapshot (Standalone)

Particulars (Rs Cr)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	H1FY25	H1FY24	YoY (%)
Total Income	315.2	420.8	-25.1	444.4	-29.1%	759.6	785.8	-3.3%
EBITDA	65.7	140.3	-53.2	128.6	-48.9%	194.3	239.6	-18.9%
EBITDA Margin	20.8%	33.4%	-1260 bps	28.9%	-810 bps	25.6%	30.5%	-490 bps
Exceptional Item	-	-	-	20.6*	-	20.6*	-	-
Profit Before Tax*	48.5	121.4	-60.0%	130.3	-62.8%	178.8	204.9	-12.7%
PBT Margin	15.4%	28.9%	-1350 bps	29.3%	-1390 bps	23.5%	26.1%	-260 bps
Profit After Tax	32.0	89.1	-64.1%	98.3	-67.5%	130.3	151.3	-13.9%
PAT Margin	10.1%	21.2%	-1110 bps	22.1%	-1200 bps	17.2%	19.3%	-210 bps
EPS (Rs.)	24.9	69.4	-64.1%	76.6	-67.5 %	101.6	117.9	-13.9%

*Q1FY25 and H1FY25 includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores

Revenue & PBT trend



Rs Cr

Sustainability Framework



Focus	Our Priorities	Our Commitments	Goal Area	Our Key Goals (included in our Executives' and Leaders' Balanced Scorecard)
	 Effluent and Waste^{3'4} Water^{3'4} Emissions and Climate Waste reduction 		Direct emissions (Scope 1 and 2)	 FY35: Carbon neutrality: 30%* reduction FY50: Net Zero in absolute emissions (subject to residual – Approx 10%)*
Environment	Change ^{3'4} R&D and Innovation^{1'4} 	Reductions in indirect emissionsSustainable R&D and Innovation	Water	FY35: Achieve 25% water neutralityFY50: Achieve 100% water neutrality
			Waste	 Maintain Zero Waste to Landfill 100% co-processing of waste Maintain Zero Liquid Discharge status of effluents
			Indirect emissions (Scope 3)	 FY35: 10%* reduction in indirect carbon emissions (including logistics)
- CO CO CO CO CO CO CO CO CO CO CO CO CO	 Occupational Health and Safety^{3,4} 	 Zero Harm People well-being and	Zero Harm	Maintain Zero FatalityMaintain Nil LTIFR
Social	 Human Capital Development^{3,4,5} Community well-being^{3,5} 	 development Human Rights Improve Diversity ESG Awareness and capability building 	People diversity	 FY30: 10% Women in Management Positions 16% of all hirings will be Women 0.5% of all employees will be PwD and Other Genders (LGBTQIA+)
Governance	 Compliance^{3,5} Business Continuity and disaster recovery^{1,2} Digitalisation² Sustainable Supply Chain^{2,5} 	 Ethics and Compliance Excellence in Corporate Governance Risk and Crisis Management Capability Integrity in reporting Sustainable supply chain 	Sustainable supply chain	FY25: Create a roadmap for sustainable supply chain with key milestones

*Aligning ESG priorities with our values: [1] Customer Centricity \rightarrow [2] Reliability \rightarrow [3] Accountability \rightarrow [4] Ownership \rightarrow [5] Openness and transparency

Glossary

Term	Description	Term	Description	
Active Pharmaceutical	Any substance that is intended for incorporation into a finished drug product and is intended to furnish pharmacological activity or other	Pipeline drugs	Drugs (small or large molecule) under development by a manufacturer	
Ingredient (API)	direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body	Prime APIs	The prime products which typically include mature APIs with relatively higher competition in API space have historically	
Biologic	Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities		contributed more than 70% of the total business.	
Biologic	such as cells and tissues.	Specialty/ Niche	Molecules in the API space which are complex in nature and are in the nature of 'high value' added products and	
Commercial molecules	Molecules where Neuland is manufacturing for commercial use after the product has been approved	APIs	Neuland's focus has been to develop these molecules from laboratory scale to large commercial quantities	
Custom Manufacturing Solutions (CMS)/ Contract Development and Manufacturing	Develop and manufacture pharmaceutical ingredients and intermediates in line with customer expectations.	Preclinical study	Preclinical studies take place in animals before any testing in humans is done.	
Organization (CDMO)	· · · · · · · · · · · · · · · · · · ·	Phase I clinical trial	Researchers test an experimental drug or treatment in a	
Development Molecules	Projects where Phase-3 is over, and molecules have been filed but not yet commercial.	Phase II clinical trial	small group of people for the first time.	
DMF	A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes, or articles used in the		The experimental drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.	
	manufacturing, processing, packaging, and storing of one or more human drugs		The experimental study drug or treatment is given to large	
GDS	Generic Drug Substance (GDS) segment which includes Prime products and Specialty products	Phase III clinical trial	groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the	
International Council for	Harmonisation project involving regulatory authorities and		experimental drug or treatment to be used safely.	
Harmonisation (ICH) Guidelines	pharmaceutical industry to improve efficiency of new drug development and registration processes		A drug that can enter cells easily because it has a low	
New Chemical Entity (NCE)	NCE is granted to "a drug that contains no active moiety that has been approved by FDA in any other application"	Small molecule products	molecular weight. Once inside the cells, it can affect other molecules, such as proteins, and may cause cancer cells to die. This is different from drugs that have a large molecular weight, which keeps them from getting inside cells easily.	
	Peptides are sequences of molecules called amino acids. Peptides of		Many targeted therapies are small-molecule drugs	
Peptides	precise sequences may occur naturally in the body, but they may also be produced synthetically or using recombinant DNA technology in bacteria and other living systems. These molecules are used to treat a variety of diseases		The US Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices 34	

Source: FDA.gov, Neuland



Thank you

For further information contact

IR Desk Neuland Labs Contact: +91 40 6761 1600 Email: mir@Neulandlabs.com

Ravi Udeshi / Minakshi Machutre EY IR Contact: +91 22 6192 2000 Email: Ravi.udeshi@in.ey.com / Minakshi.Machutre@in.ey.com

